Tyrosine kinase inhibitor oral - OV SPV2

Drug Profile

Tyrosine kinase inhibitor oral - OV SPV2

Latest Information Update: 12 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer OV-SPV2; Unknown
  • Class Antineoplastics
  • Mechanism of Action Protein-tyrosine-phosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cancer

Most Recent Events

  • 30 Dec 2016 Oncology Venture in-licenses Drug Response Prediction (DRP™) technology from Medical Prognosis Institute with three year world-wide exclusivity
  • 30 Dec 2016 Phase-III clinical trials in Cancer (PO) in Denmark
  • 01 Dec 2016 Phase-II clinical trials in Cancer (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top